Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

CETP Inhibitor Obicetrapib Moves Forward in EMA Review, With Dual Cardiovascular and Neurology Impact

by Neurology Live
0 Comments
0 Mins
The European Medicines Agency has accepted NewAmsterdam Pharma’s application for obicetrapib, an oral CETP inhibitor that lowers LDL-C and shows promise in reducing Alzheimer-related biomarkers.
Tags:
Neurology Live
Author

Neurology Live

Previous Post
Yearly Flares in Atopic Dermatitis May Predict Disease Severity
Next Post
Severe Group A Streptococcus Infection among Children, France, 2022–2024
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago